Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 8/20 | 0.74 |
| ▸ | FGFR2 | P21802 | 8/20 | 0.74 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.74 |
| ▸ | FGFR3 | P22607 | 8/20 | 0.74 |
| ▸ | SRC | P12931 | 5/20 | 0.74 |
| ▸ | ESR1 | P03372 | 6/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.58 |
| ▸ | PPARG | P37231 | 4/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4656306 | 0.96 | FGFR1 (0.68) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL4655931 | 0.92 | PPARG (0.71) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL144476 | 0.86 | FGFR1 (0.74) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL3570952 | 0.85 | PPARG (0.74) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL143675 | 0.85 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL146452 | 0.85 | FGFR1 (0.72) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL3575957 | 0.84 | FGFR1 (0.70) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL27218306 | 0.84 | FGFR1 (0.74) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL142246 | 0.81 | FGFR1 (0.65) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL147746 | 0.81 | FGFR1 (0.74) | FGFR1FGFR2FGFR4FGFR3SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745439-B2 | Indene derivatives and process for the preparation thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-06-29 | — | — | US | disclosed |
| US-20070225288-A1 | Indene Derivatives and Process for the Preparation Thereof | JEIL PHARM. CO., LTD. (KR) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225288-A1 | Indene Derivatives and Process for the Preparation Thereof | INSR, GPR119, PPARA | FGFR1 41/4885FGFR2 124/4885FGFR4 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.